Relma-cel
Phase 3Cell therapy
Relma-cel is one of 124 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.
3
Indications
5
Total Trials
4
Active Trials
123
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Relma-cel
SShanghai Ming Ju Biotechnology Co., Ltd.
Phase 3
Zofran
NovartisPreclinical
Cabenuva
GSKPreclinical
Norvir
AbbViePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma2 trials
Systemic Lupus Erythematosus2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Relma-cel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details